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genes identified by TG-LASSO for multiple drugs in a tissue were associated with patient 22 survival. In summary, our analysis suggests that preclinical samples can be used to predict 23 CDR of patients and identify biomarkers of drug sensitivity and survival. 24
25

AUTHOR SUMMARY 26
Cancer is among the leading causes of death globally and perdition of the drug response 27 of patients to different treatments based on their clinical and molecular profiles can 28 enable individualized cancer medicine. Machine learning algorithms have the potential to 29 play a significant role in this task; but, these algorithms are designed based the premise 30 that a large number of labeled training samples are available, and these samples are 31 accurate representation of the profiles of real tumors. However, due to ethical and 32 technical reasons, it is not possible to screen humans for many drugs, significantly limiting 33 the size of training data. To overcome this data scarcity problem, machine learning 34 models can be trained using large databases of preclinical samples (e.g. cancer cell line 35 cultures). However, due to the major differences between preclinical samples and real 36 tumors, it is unclear how accurately such preclinical-to-clinical computational models can 37 predict the clinical drug response of cancer patients. 38 39 Here, first we systematically evaluate a variety of different linear and nonlinear machine 40 learning algorithms for this particular task using two large databases of preclinical (GDSC) 41 and tumor samples (TCGA) . Then, we present a novel method called TG-LASSO that 42 48
INTRODUCTION 49
Cancer is one of the leading causes of death globally and is expected to be the most 50 important obstacle in increasing the life expectancy in the 21 st century [1] . Individualized 51 cancer medicine has the potential to revolutionize patient prognosis; however, two major 52 challenges in this area include the prediction of the individual responses to different 53 treatments and the identification of molecular biomarkers of drug sensitivity. While 54 factors such as cancer type or its symptoms have been traditionally used to identify the 55 treatment [2], the development of high throughput sequencing technologies [3] and 56 sophisticated machine learning (ML) approaches present the possibility of individualizing 57 treatment based on molecular 'omics' profiles of patients' tumors [4] . However, due to 58 the technical and ethical challenges of screening individuals against many drugs [5] , such 59 models are either trained for only a handful of drugs [6] or are trained using preclinical 60 samples such as 2D cancer cell line cultures (CCLs) [7] [8] [9] [10] . In spite of the success of these 61 methods in predicting the drug response of left-out preclinical samples using models 62 trained on preclinical samples, they have had limited success in predicting the CDR of real 63 patients [9, 11] , with some exceptions [12] [13] [14] . 64 65 Various preclinical models of cancer have been developed to enable the study of cancer 66 and its treatment in the laboratory. CCLs, which are 2D cell cultures developed from 67 tumor samples, are one of the least expensive and most studied of these models. 68
Recently, several large-scale studies have cataloged the molecular profiles of thousands 69 of CCLs and their response to hundreds of drugs [15] [16] [17] . Although various computational 70 models have been developed to predict the CCLs' drug response using their molecular 71 profiles [7-9], these models have shown limited success in predicting CDR in real patients. 72
In spite of sporadic successes for a handful of drugs [12, 13] , the current belief remains 73 that developing an accurate computational 'preclinical-to-clinical' model is extremely 74 difficult if not impossible [5] . Our goal in this study was to perform an unbiased systematic 75 evaluation on a panel of drugs to determine 1) whether regression models trained on in 76 vitro preclinical samples can accurately predict the CDR of real patients for each drug and 77 2) what type of side information (e.g. interaction of the genes, the tissue of origin of 78 samples) might improve the CDR prediction. 79
80
To this end, we first formed a computational framework to systematically evaluate the 81 prediction accuracy of different computational methods. We obtained preclinical training 82 samples from the Genomics of Drug Sensitivity in Cancer (GDSC) database [16] and 83 obtained molecular profiles of tumor samples from The Cancer Genome Atlas (TCGA) [18] . 84
We focused on drugs that were shared between these two datasets and utilized the gene 85 expression profiles of samples to predict the drug response, since previous studies have 86 demonstrated gene expression to be most informative for this task [7] . Our analysis 87 showed that regularized linear regression models provide the best performance among 88 various algorithms. In addition, we included prior information on the relationship among 89 genes (in the form of gene interaction networks) using several algorithms; however, this 90 prior information did not improve the prediction. 91
92
Next, we developed a novel approach called Tissue-Guided LASSO (TG-LASSO) to explicitly 93 include information on the tissue of origin of samples in the regularized regression model. 94
This method outperformed all other approaches evaluated. Using this method, we 95 showed that the CDR of cancer patients can be accurately predicted using preclinical CCL 96 training samples, for the majority of drugs. More specifically, out of 12 drugs, TG-LASSO 97 accurately separated resistant patients from sensitive patients for 7 drugs. In addition, for 98 each tissue type and drug, TG-LASSO identified a small set of genes that may be used as 99 tissue-specific biomarkers of drug response for each drug. We showed that genes selected 100 by TG-LASSO for prediction of drug response are informative of patient survival when 101 used as a gene signature, and also provide pathway-level insights into mechanisms of drug 102 action. These results emphasize the clinical relevance of molecular profiles of preclinical 103 samples cataloged in large-scale databases and demonstrate the importance of properly 104 including information on the lineage of samples in follow-up analyses. 105
106
RESULTS
107
Prediction of clinical drug response of cancer patients using in vitro experiments on 108 preclinical cancer cell lines 109
In this study, our first goal was to determine whether commonly used machine learning 110 algorithms are capable of predicting the clinical drug response (CDR) in cancer patients 111 using computational models trained only on cancer cell lines' (CCLs) basal gene expression 112 profiles (i.e. before administration of the drug) and their drug response. For this purpose, 113
we identified 23 drugs ( Supplementary Table S1 ) that were administered to patients of 114
The Cancer Genome Atlas (TCGA) [18] and were also present in the Genomics of Drug 115 Sensitivity in Cancer (GDSC) [16] database. We obtained the gene expression profiles of 116 531 primary tumor samples of TCGA patients (17 different cancer types) who were 117 administered any of these drugs from the Genomic Data Commons [19] (see Methods and 118 Supplementary Table S1 ). We obtained the carefully collected and curated information 119 on clinical drug response (CDR) of these patients from [6] . Similarly, we obtained the gene 120 expression profiles and the half-maximal inhibitory concentration (IC50) of 979 cancer cell 121 lines (of 55 different tissues) from GDSC (see Supplementary Table S1 for the number of 122 cell lines from each tissue). 
127
We formed a computational framework to systematically evaluate the prediction 128 capability of different algorithms (Fig. 1 ). In this framework, we first normalize the data 129 and remove batch effects to ensure that the gene expression profiles from these two 130 datasets are comparable (Methods). This is particularly important since GDSC contains 131 microarray gene expression values, while TCGA contains RNA-seq data. We used ComBat 132
[20] for batch effect removal, which has been previously used to successfully remove the 133 batch effect between RNA-seq and microarray data [21] (see Supplementary Fig. S1 for 134 the distribution of samples before and after batch effect removal). Next, we trained a 135 regression model to relate the gene expression profiles of CCLs to their IC50 values for a 136 specific drug. Given this model, we then estimated IC50 values for different patient 137 tumors using their gene expression profiles. Finally, we compared the estimated IC50 138 values to the true CDR of the tumors of patients treated with the same drug to determine 139 the accuracy of prediction. 140
141
We used a one-sided nonparametric Mann Whitney U test to determine whether the 142 estimated IC50 values of resistant tumors (those with CDR of 'clinical progressive disease' 143 or 'stable disease') are significantly larger than sensitive tumors (those with CDR of 'partial 144 response' or 'complete response'). In this evaluation, we only used 12 drugs that had at 145 least 2 tumor samples in each category of resistant or sensitive and had at least 8 total 146 samples with known CDR. Table 1 shows a summary of the performance of different 147 methods. In this table, we used the combined p-value of all 12 drugs (using Fisher's 148 method to combine p-values) as a measure to summarize the results of different 149 methods. Table 2 and Supplementary Table S2 contain the detailed performance of LASSO 150 and all other methods, respectively, for prediction of the CDR of each drug. We focused 151 on these methods as they have been previously used for this task (but for fewer drugs 152 and using other datasets), with different degrees of success [12, 22, 23] 22], we observed that regularized linear models resulted in the best performance, with 165 LASSO performing the best. Second, we observed that although the method proposed in 166
[5] is based on ridge regression, its performance is inferior to the ridge regression utilized 167 in our study. This is likely due to the difference between the preprocessing and batch 168 effect removal approaches used in the two studies. More specifically, instead of using 169
ComBat to homogenize the gene expression data in the preclinical and clinical samples 170 (as was done in our study and also in [12]), they simply standardized the mean of each 171 gene to zero and its variance to one. This point emphasizes the importance of data 172 181 preprocessing in pharmacogenomics studies. Third, we observed that for some drugs, the 182 CDR could be accurately predicted independent of the method, while for others, the 183 choice of the method is important. For example, the CDR of cisplatin could be accurately 184 predicted (p<0.05) using six out of the seven methods above (as an example Table 3 shows 185 that 92% of resistant patients are correctly designated using LASSO, while keeping 186 precision at ~30% and specificity at ~50%). On the other hand, only support vector 187 regression (SVR) with RBF kernel could accurately predict the CDR of temozolomide, 188 suggesting a nonlinear relationship between the gene expression values and the drug 189 response. As another example, the majority of the methods could not predict the CDR of 190 taxane-based chemotherapy agents (docetaxel and paclitaxel). We suspect that this lack 191 of success is due to the existence of various parameters that influence their response, 192 such as tissue dependence or microenvironmental factors [24, 25] , which may not be 193 captured using these simple methods trained on gene expression profiles of CCLs. In fact, 194
we later show that including the tissue of origin explicitly in the predicting model using 195 TG-LASSO can significantly improve the drug response prediction for paclitaxel. 196 197
Including information on gene interactions does not improve CDR prediction 198
Various studies have suggested that including information on the interaction of the genes 199 (and their protein products) or their involvement in different pathways can improve the 200 accuracy of different bioinformatics tasks [26] such as gene prioritization [27] , gene 201 function prediction [28] , gene set characterization [29] , and tumor subtyping [30] . Since 202 the genes (and their protein products) involved in a drugs mechanism of action 203 biochemically and functionally interact with each other, we sought to determine whether 204 including these interactions could improve CDR prediction. Since linear models provided 205 the best performance in our preliminary analyses (Table 1) , we focused on methods that 206 incorporate gene interaction networks into linear predictive models. These included 207 Supplementary Table S1 for details). Table 4 summarizes the results  221 and Supplementary Table S3 provides the details of the evaluations. These results suggest 222 that in this application, incorporating network information using these methods does not 223 improve the prediction compared to linear models (e.g. LASSO) that do not incorporate 224 such information (Table 1) . This was in spite of the fact that some of these network-guided 225 methods (e.g. NICK with STRING Text Mining) do improve the performance of within-226 dataset cross-validation (using only GDSC samples) compared to LASSO (see 227
Supplementary Methods). 228 229
Incorporating the tissue of origin to improve CDR prediction 230
Up to this point, we only used the tissue of origin of the preclinical and clinical samples 231 implicitly (through their gene expression profiles) by training a single model for a drug on 232 all CCLs of different lineages, and then using this global model to predict the response of 233 patients with different cancer types. However, due to the importance of the tissue of 234 origin in the efficacy of anticancer drugs observed in various studies [37, 38] , we sought 235 to determine whether explicitly including the tissue of origin would improve the 236 prediction of CDR, and if so, the best method for this inclusion. For our analysis, we 237 focused on variations of LASSO (without including gene interactions), which previously 238 yielded the best performance among all the tested algorithms (Table 1) . We matched the 239 lineage of the CCLs with those of cancer patients, identifying 13 shared tissue types. 240
241
One of the most common methods of including the tissue of origin in regression analysis 242 is introducing new binary features to each sample, representing whether the sample 243 belongs to that tissue ('1') or not ('0') [15] . We included 13 such binary features in the 244 analysis ('method 1'). However, the prediction results of this approach were almost 245 identical to the results of LASSO when not including any tissue information. This is not 246 surprising, since in this application the number of one type of features (i.e. genes) is much 247 larger than the number of the other type of features (i.e. tissue types). As a result, the 248 predicted drug response values will be highly biased by the influence of gene expression 249 data and the tissue of origin's influence will be overlooked. As an alternative, we trained 250 different LASSO models for each tissue type by restricting the training (CCL) and test 251 (tumor) samples to those originating from the same tissue of interest ('method 2'). For 252 tumor samples without CCLs with matching tissue, we used all CCLs to train the model. Since controls the number of features (i.e. genes) used by the LASSO model, this 271 approach allows us to optimally select the number of predictive genes for each tissue type 272 (see Methods for details), yet use all CCLs to train these tissue-specific regression models. 273 This approach resulted in the best performance among all the methods tested, with 7 (out 274 of 12) drugs showing significant discrimination between resistant and sensitive tumors 275 (p<0.05) and a combined p-value (Fisher's method for all 12 drugs) of 2.25E-10 ( Fig. 2 , 276 Table 5 and Supplementary Table S4 ). These results not only show that including the 277 tissue of origin can improve CDR prediction using preclinical samples, but also suggest 278 that the method of utilizing this information has a significant influence on the 279 performance. 280
281
One interesting observation was that paclitaxel, the response of which could not be 282 predicted accurately with the majority of methods reported in Table 1 , showed a 283 significant improvement in the response prediction with TG-LASSO (p = 0.048, one-sided 284
Mann Whitney U test), suggesting a prominent role for the tissue of origin in its drug 285 response. On the other hand, the CDR prediction of docetaxel did not improve (p = 0.99), 286 even though docetaxel is also a taxane, like paclitaxel, and these two drugs have a 287 statistically significant correlation in their CCL responses (Spearman rank correlation = 288 0.38, p = 1.7E-13). We suspected that this difference between the performance of TG-289 LASSO for docetaxel and paclitaxel is related to how well the CCL panel used for training 290 represents the tumor samples of patients to whom these drugs were administered. To 291 evaluate this, we calculated the similarity between the gene expression profiles of tumor 292 samples to those of CCLs from the same tissue of origin for these drugs. This analysis 293 showed a lower similarity between the docetaxel-administered tumors and CCLs (average 294 cosine similarity = 0.07) compared to paclitaxel-administered tumors and CCLs (average 295 cosine similarity = 0.11). These results provide evidence in favor of our hypothesis that 296 the difference in the performance of TG-LASSO is related to how well the CCLs represent 297 the profile of tumors to which these two drugs were administered. 298 299 
300
The second column shows the number of drugs for which a statistically significant discrimination between resistant and 301 sensitive patients was obtained (one-sided Mann Whitney U test). The third column shows the total number of drugs 302 included in the evaluation, and the fourth column shows the combined p-value (using Fisher's method) for all the drugs 303 in the analysis. 
305
Since some of the drugs used in our study were administered in combination with other 306 drugs, we asked how well TG-LASSO predicts the CDR in such cases of treatment with drug 307 combinations. For this purpose, we evaluated its CDR prediction for a drug only on 308 patients for whom that drug was administered over a period overlapping their treatment 309 with at least one other drug. We limited our analysis to 9 drugs with at least two samples 310 (patients) in each group (sensitive and resistant) and with at least 8 samples in total. 311 Supplementary Table S5 shows that, consistent with our previous results, TG-LASSO 312 outperforms all other methods, capable of accurately predicting the CDR of 6 (out of 9) 313 drugs (p<0.05, one-sided Mann Whitney U test). 314
Characterization of genes identified by TG-LASSO 315
During its training phase, TG-LASSO automatically selects a subset of genes to be used in 316 the regression model by tuning the hyperparameter introduced above. The number of 317 genes selected in this manner depends on the drug and tissue type for which the model 318 is trained to make response predictions and was found to range between 9 and 808 genes 319 with a median of 174 genes. The genes identified by TG-LASSO included many direct 320 targets of each drug. (For these analyses we used all 23 drugs shared between TCGA and 321 GDSC and not just those with a large number of samples in TCGA). For example, EGFR, 322 which is a direct target of both cetuximab and gefitinib [39] , was selected by this 323 algorithm when trained to predict response of these drugs in each of the 13 tissue types 324
( Supplementary Table S6 ). Similarly, FLT3, a target of the drugs sorafenib and sunitinib 325
[39], was selected by TG-LASSO for predicting response to these drugs in 13 and 12 326 tissues, respectively. In addition to direct targets, many of the identified genes have been 327
shown to be indirect targets of these drugs and to be involved in their mechanism of 328 action. For example DNER, a gene identified by TG-LASSO for all tissue types, has been 329 shown to be significantly upregulated in response to this drug in NCI-H526 cell lines [40] . 330 331 More importantly, the knockdown or overexpression of many of the identified genes has 332 been shown to influence the sensitivity of cancer cells to these drugs. For example, the 333 shRNA knockdown of CHI3L1, a gene identified for etoposide and cisplatin response in 334 every tissue, has been shown to sensitize glioma cells to these two drugs, while its 335 overexpression reduced their sensitivity [41] . As another example, the knockdown of 336 SALL4 (identified in all tissues) in cancer cell lines has been shown to increase the 337 sensitivity of lung cancer cells [42] and esophageal squamous cell carcinoma cells [43] to 338 cisplatin. Supplementary Table S7 summarizes some of the evidence we curated from 339 literature for the role of different genes identified by TG-LASSO in all tissue types for 340 cisplatin, as an illustration. These examples show the fact that the genes utilized by TG-341 LASSO in prediction of CDR of patients not only include targets of respective drugs, but 342 also include genes whose expression has been experimentally shown to predict the 343 sensitivity of these drugs: a property necessary for any predictive model of drug response. 344 345 Next, we sought to quantify the tissue specificity of identified gene sets for different 346 drugs. For this purpose, we used the Jaccard Distance (JD), which measures the distance 347 of two sets: mutual exclusive sets have JD = 100% and identical sets have JD = 0%. For 348 each drug, we calculated the JD of gene sets identified for that drug in each pair of tissues 349
( Supplementary Table S8 ). Nine out of 23 drugs had an average JD (calculated across all 350 tissue pairs) of more than 50%. Additionally, there was a high degree of variability in the 351 average JD of different drugs' gene sets, with Bleomycin having the lowest average JD of 352 23.4% and Lapatinib having the highest average JD of 65.0% ( Supplementary Fig. S3) , 353 which suggests a tissue-specific mechanism of action for the latter drug. These results 354
illustrate that TG-LASSO may identify largely different gene sets for a drug from one tissue 355 to another. 356
Genes identified for multiple drugs in a tissue are associated with patient survival 357
We hypothesized that genes that were identified by TG-LASSO as response predictors of 358 many drugs in a single tissue ( Supplementary Table S9 ) may be able to predict the survival 359 of patients who have cancer that originated from that tissue, as they may play a significant 360 role in the development and progress of the disease. To test this, we obtained gene 361 expression values of 4908 primary tumors from 10 different cancer types (corresponding 362 to the tissue types in our study) from TCGA, requiring the data to include at least 170 363 patients and 20 incidents of deaths for each cancer type ( Supplementary Table S10 ). Then, 364
we clustered the primary tumors of each cancer type into two groups based on the 365 expression of genes identified by TG-LASSO for more than 5 different drugs in the tissue 366 corresponding to that cancer type. We used hierarchical clustering with cosine similarity. 367
Kaplan-Meier survival analysis showed that this clustering approach could separate 368 patients with poor survival from those with better survival (p < 0.05) for 6 out of the 10 369 cancer types (Fig. 3, Supplementary Fig. S2 , Supplementary Table S10 ). These results 370 provide further evidence in favor of the role of these genes in the progress of the 371 corresponding cancer type. 372 373
Functional and pathway enrichment analysis of LGG related genes 374
Since Kaplan-Meier analysis using Lower Grade Glioma (LGG) patients resulted in the most 375 significant p-value (logrank test, p=7.61E-13), we sought to further characterize the 376 identified genes that resulted in this significant patient stratification using functional and 377 pathway enrichment analysis. For this purpose, we used the KnowEnG's gene set 378 characterization pipeline [26] and identified 20 gene ontology (GO) terms and two 379 pathways enriched (FDR < 0.05) in this gene set ( Supplementary Table S11 ). the expression of genes that were identified by TG-LASSO for more than 5 drugs in the corresponding tissue.
383
The p-value was calculated using a logrank test.
385
Several of the most significantly enriched GO terms were related to extracellular matrix 386 (ECM), which plays an important role in the infiltration of glioma cells into the brain [44, 387 45] . Another important GO term was neutrophil degranulation (FDR=2.1E-3) . Neutrophils 388 are the most abundant type of white blood cells and the number of infiltrating neutrophils 389 have been shown to be associated with the malignancy of glioma and its drug resistance 390
[46]. In addition, it has been shown that in patients with glioblastoma, neutrophil 391 degranulation is associated with peripheral cellular immunosuppression [47] . Another 392 noteworthy GO term was integrin binding (FDR = 0.037). Integrins are transmembrane 393 proteins that mediate cell adhesion, play an important role in promoting the invasiveness 394 of glioma cells [48] , and have been suggested as potential targets with diagnostic and 395 prognostic value in glioma [49] . Several enriched GO terms were related to the activity of 396 endopeptidases and collagen. It has been shown that the level of collagen in glioma 397 patients is increased, and it also plays a key role in promoting the tumor progression [50] . 398
Matrix metalloproteinases (MMPs) are one important class of endopeptidases that are 399 responsible for regulating the turnover of collagens, and their expression and activity has 400 been associated with the progression of human glioma [50, 51] . Finally, 'response to drug' 401 was another enriched GO term, which reflects the relevance of the identified genes to the 402 general mechanisms of drug response in a cell. 403
404
The enriched pathways included miRNA targets in ECM and membrane receptors 405 (FDR=2.0E-3) and Syndecan-1-mediated signaling (FDR=0.04). Syndecan-1 is a cell surface 406 heparan sulfate proteoglycan and its expression has been shown to be correlated with 407 tumor cell differentiation in various cancers [52] . In addition, its knockdown has been 408 shown to inhibit glioma cell proliferation and invasion and has been suggested as a 409 therapeutic target for glioma [53] . These results support our expectation that the LGG-410 related gene set not only involves drug response related genes, but also includes those 411 that play important roles in glioma and may act as diagnostic biomarkers or therapeutic 412 targets. 413
414
DISCUSSION 415
Ideally, a predictive model of CDR should be trained on data obtained directly from 416 patients. Similarly, identification of biomarkers of drug sensitivity has the most potential 417 clinical impact when based on patient data. However, since in practice most patients only 418 receive the "standard of care" treatment based on their specific cancer type, CDR data is 419 scarcely available for the newly approved drugs or drugs that have not yet passed the 420 clinical trial, limiting our ability to decipher the mechanisms of drug sensitivity for these 421
drugs. An alternative approach is to train ML models on preclinical samples (e.g. CCLs) to 422 predict the CDR of patients, then use these predictions to discover novel biomarkers and 423 druggable targets. 424
425
Recent large-scale studies that have cataloged the molecular profiles of thousands of CCLs 426
and their response to hundreds of drugs [15] [16] [17] are great resources to achieve this goal. 427
In this study, we adopted such an approach and systematically assessed a variety of ML 428 algorithms. Our analyses showed that the CDR of many drugs can be predicted using ML 429 models (especially, regularized linear models) trained on CCLs. However, by evaluating a 430 variety of methods that include auxiliary information (e.g. interaction of the genes, the 431 tissue of origin, etc.), we observed that improving the performance beyond what is 432 achievable using linear models is extremely difficult and requires careful modeling and 433 novel computational techniques. It appears that the way by which auxiliary information 434 is utilized has a large impact: for example, several methods that include the tissue of origin 435 did not improve the results obtained by LASSO, and only TG-LASSO could improve the 436 performance. Additionally, we showed that TG-LASSO identifies tissue-specific gene sets 437 for each drug that include various targets of the drug, genes involved in the drug's 438 mechanism of action, and genes whose under-or over-expression could sensitize cancer 439 cells to the drug. Moreover, these sets include genes that are involved in cancer 440 progression and are associated with patient survival. These results suggest that in 441 addition to a superior drug response prediction performance, TG-LASSO can identify 442 biomarkers of patient survival and drug sensitivity. 443
444
We note that due to the major differences between CCLs and tumors (e.g. the greater 445 heterogeneity of cells in a tumour compared to CCLs), obtaining more accurate results 446 based on classical ML techniques may not be possible. The reason is that classical ML 447 methods assume that the training samples and the test samples are drawn from the same 448 or similar distributions. While batch effect removal and other homogenization and 449 normalization techniques help to alleviate this issue, more realistic preclinical models of 450 cancer are necessary to significantly improve these results. Recent advances in 451 developing human derived xenografts [54] and 3D human organoids [55] may enable 452 developing a more accurate predictive model of CDR in cancer. However, due to the 453 current high cost of these models, a more practical approach is developing computational 454 methods that explicitly model these differences. Such methods must go beyond utilizing 455 bulk gene expression data and take advantage of multi-omics analysis of bulk and single-456 cell sequencing profiles of samples. Due to the rapid advances in these domains, we 457 expect that large databases of single-cell multi-omics profiles of preclinical and clinical 458 samples and their drug response will become available in the near future. 459 460 METHODS 461
Datasets, preprocessing and batch effect removal 462
We obtained the gene expression profiles (FPKM values) of 531 primary tumor samples 463 of TCGA patients who were administered any of the 23 drugs mentioned earlier. First, we 464 removed genes that contained missing values. We also removed any gene that was not 465 expressed (i.e. FPKM<1) for more than 90% of the samples. Then, we performed a log-466 transformation and obtained log2(FPKM+0.1) values for each gene. The resulting gene 467 expression matrix contained 19,437 genes and 531 samples. We obtained the CDR of 468 these patients from the supplementary files of [6] (see the original paper for their 469 approach in curating this data from TCGA). Similarly, we obtained the Robust Multi-array 470 Average (RMA)-normalized basal gene expression profiles and the logarithm of half 471 maximal inhibitory concentration, log(IC50), of 979 cancer cell lines from GDSC 472
( Supplementary Table S1 ) for 17,737 genes. 473
474
To homogenize the gene expression data from these two datasets, we first removed 475 genes not present in both datasets as well as genes with low variability across all the 476 samples (standard deviation < 0.1), resulting in a total of 13,942 shared genes. Then, we 477 used ComBat [20] for batch effect removal to homogenize the gene expression data from 478 TCGA (RNA-seq) and GDSC (microarray). This approach, which has been previously used 479 to successfully homogenize these two data types [21] , removed the batch effect present 480 in the gene expression datasets (see Supplementary Fig. S1 ). For all follow-up analysis, we 481 Table S1 . 489 490
Machine learning regression models 491
The baseline models (Table 1) were all implemented using the Scikit-learn [56] in Python 492 and the hyperparameters were selected using cross validation (using only CCL samples). 493
For the network-based algorithms (Table 4) , we used four networks summarized in 494 Supplementary Table S1 . We used the normalized graph Laplacian of these networks to 495 run GELnet [31]. This method forces neighboring genes in the graph to have similar 496 weights in order to guide drug response prediction. Specifically, it defines a regularization 497 penalty ( ) for the standard linear model. Furthermore, we used Network-Induced Classification Kernels (NICK), a method closely 502 related to GELnet. The NICK framework is actually a special case of the GELnet, with = 503 ( + ) for some ≥ 0 and = 0 . The parameter provides a trade-off between 504 graph-driven regularization and the traditional ridge regression penalty of the SVMs. 505
506
In addition to the above methods that utilize the graph Laplacian of each network in the 507 regression algorithm, we used sparse group LASSO (SGL). This method takes a collection 508 of pathways as input and induces sparsity at both the pathway and the gene level to 509 generate the input. We performed community detection on each of the networks in Table  510 4 by maximizing the modularity using the Louvain heuristics [57] to identify gene sets to 511 be used in the SGL algorithm. We then ran SGL by fitting a regularized generalized linear 512 model with group memberships of genes as deemed by the community detection to 513 predict drug response. 514 515 Finally, we developed a heuristic method based on ssGSEA [34] followed by LASSO. In this 516 method, we used ssGSEA to assign a score to each sample for the enrichment of its gene 517 expression profile in communities of each network, obtained earlier. These scores where 518 then used as features to train a LASSO model for prediction of CDR. 519 520
Methods for including tissue of origin in CDR prediction 521
In the first approach (Method 1 in Table 5 ), we augmented the gene expression profile of 522 each sample (both CCLs and tumors) with binary features corresponding to different 523 tissues of origin shared between the TCGA and GDSC samples (a total of 13 features). For 524 each sample its tissue of origin was assigned a value of '1', and other tissues were assigned 525 a value of '0'. Then, the LASSO algorithm was used to train a drug response model on CCLs 526 and predict the CDR of tumors. 527
528
In the second approach (Method 2 in Table 5 ), we trained different LASSO models for each 529 drug-tissue pair (23 drugs and 13 tissue types). More specifically, to predict the CDR of 530 drug in a tumor of tissue , we trained a LASSO regression model using the IC50 of drug 531 in only cell lines corresponding to tissue (i.e. a subset of the training samples). For 532 tumors originating in tissues without matching training CCLs, we used all the CCLs to train 533 the model. 534
535
Prediction of CDR in cancer tumors using Tissue-guided LASSO 536 TG-LASSO is a method for predicting the CDR of tumors using the information in all 537 training samples (originating from different tissue lineages), while incorporating 538 information on the tissue of origin of the samples. By utilizing all the training samples, it 539 overcomes the lack of generalizability stemming from limited number of CCLs from each 540 tissue type, a major issue in Method 2 above. In addition, by incorporating the 541 information on the tissue of origin of the samples in the training step, it improves the 542 performance of tissue-naïve regression methods, such as those in Table 1 . is the number of training samples, is the response vector of length , is an × 546 feature matrix ( is the number of features), ‖ ‖ / denotes the L2 vector norm, ‖ ‖ ) 547 denotes the L1 vector norm, and is the hyperparameter that determines the sparsity of 548 the model (i.e. number of features used in training). The hyperparameter tuning is usually 549 achieved independent of the structure of the training samples (e.g. their tissue of origin), 550 for example using random cross-validation or a regularization path. However, we and 551 others [58] have shown that including the group structure of data in selecting the 552 hyperparameter is important in assessing the generalizability of regression models. 553 Motivated by these results, even though TG-LASSO utilizes the gene expression and the 554 drug response of all CCLs in training, the hyperparameter is selected in a tissue-and 555 drug-specific manner, as explained below. 556 557 Let be the set of all drugs and be the set of all tissues in the test set (i.e. the TCGA 558 dataset). To train a model to predict the CDR of tumor samples from tissue ∈ to drug 559 ∈ , we identify all the training CCLs corresponding to tissue and use them as the 560 validation set. In addition, we use all other CCLs as the training set. Then, the 561 hyperparameter is selected as the one that obtains the best accuracy on predicting the 562 IC50 values of the samples of tissue in the validation set. Designing the hyperparameter-563 tuning step such that the validation and the test sets have the same tissues of origin 564 ensures that the value of is selected so as to generalize well to the test set. The obtained 565 value of is then used with all CCLs (including those from tissue ) to fit a model 566 minimizing the LASSO objective function. In the prediction step, this fitted model is then 567 used with the gene expression of tumor samples from tissue to predict their CDR. 568 569
Gene ontology and pathway enrichment analysis 570
We used the gene set characterization pipeline of KnowEnG analytical platform [26] for 571 this analysis, which utilizes Fisher's exact test to determine the significance of 572 enrichments. We excluded GOs or pathways with too few genes, focusing only on those 573 with more than 10 members. For the pathway analysis, we used the Enrichr pathways 574
[59] available on KnowEnG. All p-values were corrected for multiple hypothesis testing 575 using Benjamini-Hochberg false discovery rate, available as part of the python module 576 
